Raile K, Hille R, Laue S, Schulz A, Pfeifer G, Horn F, Kiess W
Research Laboratory, Hospital for Children and Adolescents, Faculty of Medicine, University of Leipzig, Leipzig, Germany.
Horm Metab Res. 2003 Nov-Dec;35(11-12):786-93. doi: 10.1055/s-2004-814140.
Insulin-like growth factor-I (IGF-I) was found to promote proliferation, cell survival, and inhibition of apoptosis. But in some instances, IGF-I was found to mildly induce apoptosis, i. e. Fas-mediated apoptosis in human MG63 osteosarcoma cells. In the present study, we intended to further investigate IGF-I dependent pathways leading either to proliferation and cell survival or to cell death. MG63 osteosarcoma cells were treated with serum free medium alone or in combination with IGF-I, a neutralizing antibody against the human IGF-I receptor (alphaIR-3) or non-immune control IgG (1) for two to six days. We investigated cell survival (cell count), proliferation (CD71-FACS), apoptosis (Annexin-V-FACS, Caspase-3 activity, PCD) and anti-apoptosis (112-Ser Bad phosphorylation), and regulation of IGF-I receptor surface expression (IGF-I receptor-FACS). We found that IGF-I treatment (48 h) stimulated cell growth and proliferation, but also mildly induced apoptosis. IGF-I activated specific apoptotic pathways (Caspase-3 activation, Annexin-V binding and DNA degradation), as well as anti-apoptotic signals (Bad phosphorylation at serine 112). alphaIR-3 blocked cell proliferation, strongly induced apoptosis, and inhibited Bad-phosphorylation. Thus, IGF-I treatment overall resulted in increased tumour cell mass, despite a detectable stimulation of apoptosis; in other words proliferation exceeded cell death. If IGF-I was first added on day 0, 2, or 4 of serum free culture, we found decreasing IGF-I specific effects on proliferation and apoptosis. In parallel, we found a down-regulation of IGF-I receptors (FACS) by serum withdrawal, which was partly reversed if IGF-I was added. Therefore receptor number might have an impact on IGF-I function in MG63 cells. In conclusion, co-activation of apoptosis and proliferation by IGF-I might result in higher cell turnover in MG63 osteosarcoma cells. Furthermore, in sarcomas or carcinomas showing clinical association to IGF-I levels and malignancy, IGF-I dependent apoptosis and proliferation could be a significant mechanism of malignant tumour growth.
胰岛素样生长因子-I(IGF-I)被发现可促进细胞增殖、存活并抑制细胞凋亡。但在某些情况下,IGF-I被发现可轻度诱导细胞凋亡,例如在人MG63骨肉瘤细胞中诱导Fas介导的细胞凋亡。在本研究中,我们旨在进一步研究依赖IGF-I的信号通路,这些通路要么导致细胞增殖和存活,要么导致细胞死亡。将MG63骨肉瘤细胞单独用无血清培养基处理,或与IGF-I、抗人IGF-I受体的中和抗体(αIR-3)或非免疫对照IgG(1)联合处理两到六天。我们研究了细胞存活(细胞计数)、增殖(CD71-FACS)、凋亡(膜联蛋白-V-FACS、半胱天冬酶-3活性、PCD)和抗凋亡(112-丝氨酸Bad磷酸化),以及IGF-I受体表面表达的调节(IGF-I受体-FACS)。我们发现,IGF-I处理(48小时)可刺激细胞生长和增殖,但也可轻度诱导细胞凋亡。IGF-I激活了特定的凋亡信号通路(半胱天冬酶-3激活、膜联蛋白-V结合和DNA降解),以及抗凋亡信号(丝氨酸112处的Bad磷酸化)。αIR-3可阻断细胞增殖,强烈诱导细胞凋亡,并抑制Bad磷酸化。因此,尽管可检测到IGF-I对细胞凋亡有刺激作用,但IGF-I处理总体上导致肿瘤细胞数量增加;换句话说,增殖超过了细胞死亡。如果在无血清培养的第0、2或4天首先添加IGF-I,我们发现IGF-I对增殖和凋亡的特异性作用会降低。同时,我们发现血清饥饿可下调IGF-I受体(FACS),如果添加IGF-I,这种下调会部分逆转。因此,受体数量可能会影响MG63细胞中IGF-I的功能。总之,IGF-I对凋亡和增殖的共同激活可能导致MG63骨肉瘤细胞中更高的细胞周转率。此外,在与IGF-I水平和恶性程度存在临床关联的肉瘤或癌中,依赖IGF-I的凋亡和增殖可能是恶性肿瘤生长的重要机制。